Amid controversial Sarepta approval decision, FDA head calls for key study retraction
The head of the U.S. Food and Drug Administration (FDA) has called for the retraction of a study about a drug that the agency itself approved earlier this week, despite senior staff opposing the approval. On September 19, the FDA okayed eteplirsen to treat Duchenne muscular dystrophy (DMD), a rare genetic disorder that results in muscle degeneration and … Continue reading Amid controversial Sarepta approval decision, FDA head calls for key study retraction